NASDAQ · RAPT
RAPT Therapeutics, Inc.
$58.01+$0.00 (0.0%)
RAPT Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.03% below the high.
Loading market information…
NASDAQ · NMRA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Neumora Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Neumora Therapeutics, Inc. Common Stock’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neumora Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 3, 2025 | -$0.37+19.57% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.45-18.42% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $4.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$58.01+$0.00 (0.0%)
RAPT Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.03% below the high.
$18.95+$1.07 (+5.98%)
Omeros Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.78% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$1.48-$0.01 (-0.34%)
Lexicon Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
$8.88-$0.22 (-2.42%)
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
$1.58-$0.05 (-3.07%)
Autolus Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$3.77+$0.02 (+0.53%)
Fulcrum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.05% below the high.
